Abstract: With the rapid advancements in pancreatic cancer diagnosis and treatment research, the Chinese Society of Clinical Oncology (CSCO) has released two editions of pancreatic cancer diagnosis and treatment guidelines in 2022 and 2024.The present article systematically compares the differences between the two editions in terms of diagnostic stratification, treatment pathways, and supportive management. By integrating insights from cutting-edge international research, the scientific rationale and clinical value of the underlying guideline revisions are explored. Clinicians are encouraged to adopt the new guidelines to dynamically assess the biological characteristics and treatment tolerance of patients, thereby formulating personalized diagnosis and treatment plans that ultimately lead to the synergistic enhancement of both survival benefits and quality of life for patients.